Shelf life (days): 730.0
Formulation: A solid
Formal Name: 4-[3-chloro-4-[[(cyclopropyl-2,2,3,3-d4-amino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide
Purity: ≥99% deuterated forms (d1-d4)
Formula Markup: C21H15D4ClN4O4
Formula Weight: 430.87706
CAS Number: 2264050-65-7
Notes: Lenvatinib-d4 is intended for use as an internal standard for the quantification of lenvatinib (Item No. 19375) by GC- or LC-MS. Lenvatinib is an inhibitor of the receptor tyrosine kinases VEGF receptor 2 (VEGFR2) and VEGFR3 (IC50s = 4.0 and 5.2 nM, respectively).{32663,32664} It is slightly less potent against the related kinases VEGFR1, FGFR1, PDGFRα, PDGFRβ, and Kit (IC50s = 22, 46, 51, 39, and 100 nM, respectively).{32663} Lenvatinib (30 mg/kg, twice per day) reduces tumor growth in an H146 small cell lung cancer mouse xenograft model and induces tumor regression when administered at a dose of 100 mg/kg twice per day. Formulations containing lenvatinib have been used in the treatment of differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.
English
Deutsch
